Item type | Home library | Collection | Class number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|
UNKNOWN | Ferriman information and Library Service (North Middlesex) Online | Staff publications for NMDX | Available |
NMUH Staff Publications
14
<br /><div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">BACKGROUND:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;"><span class="highlight">Incidence</span>&nbsp;and&nbsp;<span class="highlight">risk factors</span>&nbsp;of HIV-associated&nbsp;<span class="highlight">non-Hodgkin</span>'s&nbsp;<span class="highlight">lymphoma</span>&nbsp;(NHL) are not well defined in the&nbsp;<span class="highlight">era</span>&nbsp;of&nbsp;<span class="highlight">combination</span>&nbsp;<span class="highlight">antiretroviral</span>&nbsp;<span class="highlight">therapy</span>&nbsp;(cART).</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">A total of 56,305 adult HIV type-1 (HIV-1)-infected patients who started cART in 1 of 22 prospective studies in Europe were included. Weibull random effects models were used to estimate hazard ratios (HRs) for developing systemic NHL and included CD4(+) T-cell counts and viral load as time-updated variables.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain&nbsp;<span class="highlight">lymphoma</span>&nbsp;(PBL). The&nbsp;<span class="highlight">incidence</span>&nbsp;rate of systemic NHL was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 (95% confidence interval [CI] 0.37-0.53). The corresponding<span class="highlight">incidence</span>&nbsp;rates of PBL were 57 and 24 per 100,000 person-years (rate ratio 0.43, 95% CI 0.25-0.73). Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing &lt; or =500 with 10,000-99,999 copies/ml) and increases in CD4(+) T-cell counts (HR 0.30, 0.22-0.42, comparing &gt; or =350 with 100-199 cells/microl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of AIDS), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing &gt; or =50 with 16-29 years) were&nbsp;<span class="highlight">risk factors</span>&nbsp;for systemic NHL.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">CONCLUSIONS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">The&nbsp;<span class="highlight">incidence</span>&nbsp;rates of both systemic NHL and PBL were substantially reduced in patients on cART. Timely initiation of&nbsp;<span class="highlight">therapy</span>&nbsp;is key to the prevention of NHL in the&nbsp;<span class="highlight">era</span>&nbsp;of cART.</span></p></div>
There are no comments on this title.